Switch to: Citations

Add references

You must login to add references.
  1. National Biobanks: Clinical Labor, Risk Production, and the Creation of Biovalue.Catherine Waldby & Robert Mitchell - 2010 - Science, Technology, and Human Values 35 (3):330-355.
    The development of genomics has dramatically expanded the scope of genetic research, and collections of genetic biosamples have proliferated in countries with active genomics research programs. In this essay, we consider a particular kind of collection, national biobanks. National biobanks are often presented by advocates as an economic ‘‘resource’’ that will be used by both basic researchers and academic biologists, as well as by pharmaceutical diagnostic and clinical genomics companies. Although national biobanks have been the subject of intense interest in (...)
    Download  
     
    Export citation  
     
    Bookmark   19 citations  
  • Harnessing the Benefits of Biobanks.Lori B. Andrews - 2005 - Journal of Law, Medicine and Ethics 33 (1):22-30.
    We have a thriving biotechnology industry in the United States. There are over 1,450 biotechnology companies developing diagnostic and treatment technologies in medicine, creating more nutritional foods, and innovating new industrial processes. Yet this $28.5 billion sector of the economy is not without controversy. The “bio” in biotechnology comes from living, biological entities - people, plants, animals, and even bacteria. In the realm of biobanking, people are the source of the raw material for the discovery of genes for research, diagnosis, (...)
    Download  
     
    Export citation  
     
    Bookmark   11 citations  
  • We’re not in it for the money—lay people’s moral intuitions on commercial use of ‘their’ biobank.Kristin Solum Steinsbekk, Lars Øystein Ursin, John-Arne Skolbekken & Berge Solberg - 2013 - Medicine, Health Care and Philosophy 16 (2):151-162.
    Great hope has been placed on biobank research as a strategy to improve diagnostics, therapeutics and prevention. It seems to be a common opinion that these goals cannot be reached without the participation of commercial actors. However, commercial use of biobanks is considered morally problematic and the commercialisation of human biological materials is regulated internationally by policy documents, conventions and laws. For instance, the Council of Europe recommends that: “Biological materials should not, as such, give rise to financial gain”. Similarly, (...)
    Download  
     
    Export citation  
     
    Bookmark   12 citations  
  • (4 other versions)Currents in Contemporary Ethics.Mark A. Rothstein - 2010 - Journal of Law, Medicine and Ethics 38 (2):412-419.
    The 2009 pandemic of influenza A was relatively mild, but a subsequent outbreak of pandemic influenza could be much worse. According to projections from the Department of Health and Human Services, the potential health consequences of a severe influenza pandemic in the United States could be literally overwhelming: up to 1.9 million deaths; 90 million people sick; 45 million people needing outpatient care; 9.9 million people hospitalized, of whom 1.485 million would need treatment in an intensive care unit ; and (...)
    Download  
     
    Export citation  
     
    Bookmark   11 citations  
  • (4 other versions)Currents in Contemporary Ethics.Mark A. Rothstein - 2002 - Journal of Law, Medicine and Ethics 30 (1):105-108.
    In the post-genome world of biomedical research, an increasingly common research strategy is to focus on large repositories of biological specimens. There are now several well-known efforts to compile vast collections of biological materials, reanalyze extant samples, collect new ones, and link the samples to medical records. The significant issues of law, ethics, and policy raised by these research activities usually are heightened when commercial enterprises play a leading role in accumulating and distributing the samples. Emerging companies are not only (...)
    Download  
     
    Export citation  
     
    Bookmark   17 citations  
  • A Trade Secret Model for Genomic Biobanking.John M. Conley, Robert Mitchell, R. Jean Cadigan, Arlene M. Davis, Allison W. Dobson & Ryan Q. Gladden - 2012 - Journal of Law, Medicine and Ethics 40 (3):612-629.
    The current ethical norms of genomic biobanking creating and maintaining large repositories of human DNA and/or associated data for biomedical research have generated criticism from every angle, at both the practical and theoretical levels. The traditional research model has involved investigators seeking biospecimens for specific purposes that they can describe and disclose to prospective subjects, from whom they can then seek informed consent. In the case of many biobanks, however, the institution that collects and maintains the biospecimens may not itself (...)
    Download  
     
    Export citation  
     
    Bookmark   6 citations  
  • DNA databanks and consent: A suggested policy option involving an authorization model.Daar Abdallah, E. G. Upshur Ross & Caulfield Timothy - 2003 - BMC Medical Ethics 4 (1):1.
    Background Genetic databases are becoming increasingly common as a means of determining the relationship between lifestyle, environmental exposures and genetic diseases. These databases rely on large numbers of research subjects contributing their genetic material to successfully explore the genetic basis of disease. However, as all possible research questions that can be posed of the data are unknown, an unresolved ethical issue is the status of informed consent for future research uses of genetic material. Discussion In this paper, we discuss the (...)
    Download  
     
    Export citation  
     
    Bookmark   9 citations